生物酶由于其特有的高催化效率、高特異選擇性、溫和的反應(yīng)條件及更少的三廢排放等優(yōu)點(diǎn)，在制藥工業(yè)中的現(xiàn)實(shí)效應(yīng)不斷擴(kuò)大，尤其在過(guò)程替代、實(shí)現(xiàn)更綠色的制藥工藝中發(fā)揮了重要作用，其重要地位獲得了廣泛認(rèn)可。本公司針對(duì)多種用于制備手性中間體的特種酶進(jìn)行了研究開發(fā)，包括羰基還原酶、醇脫氫酶、轉(zhuǎn)氨酶、脂肪酶、?；?、腈水解酶等。綜合各大客戶所反饋工業(yè)數(shù)據(jù)，相比原化學(xué)轉(zhuǎn)化或拆分工藝，在采用生物酶工藝后，反應(yīng)總收率平均提高10%以上，單位時(shí)間產(chǎn)品產(chǎn)率平均提高40%-50%，三廢排放降低20%以上。

酶法催化已經(jīng)在阿托伐他汀、瑞舒伐他汀、度洛西汀、西他列汀等重磅藥物的生產(chǎn)中獲得了廣泛應(yīng)用。

Due to its unique advantages of high catalytic efficiency, high specificity, mild reaction conditions and less waste emissions, biological enzymes in the pharmaceutical industry, the practical effect of expanding, especially in the process of replacement, to achieve a greener pharmaceutical process has played an important role, its important status has been widely recognized. The company has developed a variety of enzymes for the preparation of chiral intermediates, including carbonyl reductase, alcohol dehydrogenase, transaminase, lipase, acylase, nitrile hydrolase, etc. . According to the industrial data from the customers, the total yield of the reaction is increased by more than 10% , and the product yield per unit time is increased by 40% -50% , reduce the discharge of three wastes by more than 20% . Enzyme catalysis has been widely used in the production of Atorvastatin, rosuvastatin, Duloxetine, sitagliptin and other blockbuster drugs.

酶應(yīng)用反應(yīng)舉例：